medigraphic.com

2016, Number S1

<< Back

Rev Med Inst Mex Seguro Soc 2016; 54 (S1)

Hypertension during pregnancy: the challenge continues

Rosas-Peralta M, Borrayo-Sánchez G, Madrid-Miller A, Ramírez-Arias E, Pérez-Rodríguez G

Language: Spanish
References: 160
Page: 90-111
PDF size: 462.44 Kb.


ABSTRACT

Hypertensive disorders of pregnancy affect approximately from 5 to 10 % of all pregnant women, and are the main contributors of maternal and neonatal morbidity and mortality worldwide. This group of disorders includes chronic hypertension, as well as the conditions that arise de novo in pregnancy: gestational hypertension and preeclampsia. This last group is believed to be part of the same continuum, but with arbitrary division. Research on the etiology of hypertension in pregnancy largely have focused on preeclampsia, with a majority of studies that explore any factor associated with pregnancy, e.g., the answers derived from the placenta or immunological reactions to tissue from the pregnancy or maternal constitutional factors, such as cardiovascular health and endothelial dysfunction. The basic foundations for the pathophysiology and progression of hypertensive pregnancy disorders, particularly preeclampsia, are reviewed in this paper. Therapeutic options for the treatment of preeclampsia are also explored.


REFERENCES

  1. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323-33.

  2. Lindheimer MD Taler SJ, Cunningham FG. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich). 2009;11(4):214-25.

  3. Lo JO, Mission JF, Caughey AB. Hypertensive disease of pregnancy and maternal mortality. Curr Opin Obstet Gynecol. 2013;25(2):124-32.

  4. Foo L, Bewley S, Rudd A. Maternal death from stroke: a thirty year national retrospective review. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):266-70.

  5. Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 1998;54(6):2056-63.

  6. Duvekot JJ, Cheriex EC, Pieters FA, Menheere PP, Peeters LH. Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol. 1993;169(6):1382-92.

  7. Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM. Maternal cardiovascular changes from prepregnancy to very early pregnancy. J Hypertens. 2012;30(11):2168-72.

  8. Hibbard JU, Shroff SG, Lang RM. Cardiovascular changes in preeclampsia. Semin Nephrol. 2004;24(6):580-7.

  9. MacGillivray I, Rose GA, Rowe B. Blood pressure survey in pregnancy. Clin Sci. 1969;37(2):395-407.

  10. Fujime M, Tomimatsu T, Okaue Y, Koyama S, Kanagawa T, Taniguchi T, Kimura T. Central aortic blood pressure and augmentation index during normal pregnancy. Hypertens Res. 2012;35(6):633-8.

  11. Simmons LA, Gillin AG, Jeremy RW. Structural and functional changes in left ventricle during normotensive and preeclamptic pregnancy. Am J Physiol Heart Circ Physiol. 2002;283(4):H1627-33.

  12. Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obstet Gynaecol. 1987;94(11):1028-39.

  13. Chung E, Leinwand LA. Pregnancy as a cardiac stress model. Cardiovasc Res. 2014;101(4):561-70.

  14. Lees MM, Scott DB, Kerr MG, Taylor SH. The circulatory effects of recumbent postural change in late pregnancy. Clin Sci. 1967;32(3):453-65.

  15. Yoder SR, Thornburg LL, Bisognano JD. Hypertension in pregnancy and women of childbearing age. Am J Med. 2009;122(10):890-5.

  16. Brown MA, Gallery ED. Volume homeostasis in normal pregnancy and preeclampsia: physiology and clinical implications. Baillieres Clin Obstet Gynaecol. 1994;8(2):287-310.

  17. Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy. 2012;article 105918:1-19. doi:10.1155/2012/105918

  18. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, et al. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet. 1993;4(1):59-61.

  19. Schroeder BMO. American College of Obstetricians and Gynecologists. ACOG practice bulletin on diagnosing and managing preeclampsia and eclampsia. Am Fam Physician. 2002;66(2):330-1.

  20. National Institute for Health and Clinical Excellence (NICE). (CG62) Antenatal care, routine care for the healthy pregnant woman. 2008, RCOG Press: Royal College of Obstetricians & Gynaecologists.

  21. Brown MA, Robinson A, Bowyer L, Buddle ML, Martin A, Hargood JL, et al. Ambulatory blood pressure monitoring in pregnancy: what is normal? Am J Obstet Gynecol. 1998;178(4):836-42.

  22. Churchill D, Beevers DG. Differences between office and 24-hour ambulatory blood pressure measurement during pregnancy. Obstet Gynecol. 1996;88(3):455-61.

  23. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol, 2000. 183(1): p. S1-S22.

  24. National Institute for Health and Clinical Excellence (NICE). (CG107) Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. 2011: London.

  25. Paruk F, Moodley J. Untoward effects of rapid-acting antihypertensive agents. Best Pract Res Clin Obstet Gynaecol. 2001;15(4):491-506.

  26. Redman C. Hypertension, in medical disorders in obstetric practice. M.d. Swiet, Editor. 2002, Blackwell Publishing Company. pp. 159-197.

  27. Valensise HNG, Vasapollo B. Preeclampsia: one name, two conditions—the case for early and late disease being different. Fetal Mat Med Rev. 2014;24:32-7.

  28. Ferrazzi EST, Aupont JE. The evidence for late-onset preeclampsia as a maternogenic disease of pregnancy. J Fetal Mat Med Rev. 2013;24(1):18-31.

  29. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008;51(4):970-5.

  30. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet. 2005;365(9461):785-99.

  31. Levine RJ; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005.

  32. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-83.

  33. Xiong X, Demianczuk NN, Saunders LD, Wang FL, Fraser WD. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol. 2002;155(3):203-9.

  34. Brosens I, Pijnenborg R, Vercruysse L, Romero R. The Great Obstetrical Syndromes are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193-201.

  35. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009;30(6):473-82.

  36. Hunkapiller NM, Gasperowicz M, Kapidzic M, Plaks V, Maltepe E, Kitajewski J, et al. A role for Notch signaling in trophoblast endovascular invasion and in the pathogenesis of preeclampsia. Development. 2011;138(14):2987-98.

  37. Cobellis L, Mastrogiacomo A, Federico E, Schettino MT, De Falco M, Manente L, et al. Distribution of Notch protein members in normal and preeclampsia-complicated placentas. Cell Tissue Res. 2007;330(3):527-34.

  38. Sahin Z, Acar N, Ozbey O, Ustunel I, Demir R. Distribution of Notch family proteins in intrauterine growth restriction and hypertension complicated human term placentas. Acta Histochem. 2011;113(3):270-6.

  39. Staff AC, Dechend R, Pijnenborg R. Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health. Hypertension. 2010;56(6):1026-34.

  40. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49(25):2379-93.

  41. Staff AC, Dechend R, Redman CW. Review: preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses. Placenta. 2013;34(Suppl):S73-8.

  42. Sheppard BL, Bonnar J. The ultrastructure of the arterial supply of the human placenta in pregnancy complicated by fetal growth retardation. Br J Obstet Gynaecol. 1976;83(12):948-59.

  43. Prins JR, Boelens HM, Heimweg J, van der Heide S, Dubois AE, Van Oosterhout AJ, et al. Preeclampsia is associated with lower percentages of regulatory T cells in maternal blood. Hyper Pregnancy. 2009;28(3):300-11.

  44. Wallace K, Richards S, Dhillon P, Weimer A, Edholm ES, Bengten E, et al. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension. 2011;57(5):949-55.

  45. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granjer JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2008;294(2):H541-50.

  46. Krauss T, Kuhn W, Lakoma C, Augustin HG. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obstet Gynecol. 1997;177(2):443-9.

  47. Roberts JM, Taylor RN, Goldfien A. Endothelial cell activation as a pathogenetic factor in preeclampsia. Semin Perinatol. 1991;15(1):86-93.

  48. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009;24:147-58.

  49. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75(1):1-8.

  50. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, et al. Pilot study of extracorporeal removal of soluble Fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124(8):940-U178.

  51. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 2007;50(4):686-92.

  52. Izumi H, Garfield RE, Makino Y, Shirakawa K, Itoh T. Gestational changes in endothelium-dependent vasorelaxation in human umbilical artery. Am J Obstet Gynecol. 1994;170(1 Pt 1):236-45.

  53. Nathan L, Cuevas J, Chaudhuri G. The role of nitric oxide in the altered vascular reactivity of pregnancy in the rat. Br J Pharmacol. 1995;114(5):955-60.

  54. Crane MS, Rossi AG, Megson IL. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol. 2005;144(6):849-59.

  55. Kubes P, Suzuki M, Granger DN. Nitric-oxide—an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88(11):4651-5.

  56. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop preeclampsia. Lancet. 2003;361(9368):1511-7.

  57. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11-13 weeks’ gestation and risk of preeclampsia. Ultrasound Obstet Gynecol. 2012;40(1):28-34.

  58. Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52(5):873-80.

  59. Melchiorre, K., Sutherland GR, Liberati M, Thilaganathan B. Maternal cardiovascular impairment in pregnancies complicated by severe fetal growth restriction. Hypertension. 60(2):437-43.

  60. Duvekot JJ, Cheriex EC, Pieters FA, Peeters LL. Severely impaired fetal growth is preceded by maternal hemodynamic maladaptation in very early-pregnancy. Acta Obstetricia et Gynecol Scandinav. 1995;74(9):693-7.

  61. Ayuk PT, Matijevic R. Placental ischaemia is a consequence rather than a cause of preeclampsia. Med Hypotheses. 2006;67(4):792-5.

  62. Everett TR, Lees CC. Beyond the placental bed: placental and systemic determinants of the uterine artery Doppler waveform. Placenta. 33(11):893-901.

  63. Harrington K, Thompson MO, Carpenter RG, Nguyen M, Campbell S. Changes observed in Doppler studies of the fetal circulation in pregnancies complicated by preeclampsia or the delivery of a small-for-gestationalage baby. I. Cross-sectional analysis. Ultrasound Obstet Gynecol. 1995;6(1):19-28.

  64. Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH. One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks’ gestation. Obstet Gynecol. 2000;96(4):559-64.

  65. Lees C, Parra M, Missfelder-Lobos H, Morgans A, Fletcher O, Nicolaides KH. Individualized risk assessment for adverse pregnancy outcome by uterine artery Doppler at 23 weeks. Obstet Gynecol. 2001;98(3):369-73.

  66. Verlohren, S, Melchiorre K, Khalil A, Thilaganathan B. Uterine artery Doppler, birthweight and timing of preeclampsia onset: providing insights into the dual etiology of late-onset preeclampsia. Ultrasound Obstet Gynecol, 2014. Sep;44(3):293-8. doi: 10.1002/ uog.13310. Epub 2014 Jul 21.

  67. Magnussen EB, Vatten LJ, Lund-Nilsen TI, Salvesen KA, Davey Smith G, Romundstad PR. Prepregnancy cardiovascular risk factors as predictors of preeclampsia: population based cohort study. Br Med J. 2007;335(7627):978-81.

  68. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohort study. Br Med J. 2001;323(7323):1213-6.

  69. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005;366(9499):1797-803.

  70. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56(1):166-71.

  71. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001;357(9273):2002-6.

  72. Talaulikar VAS. HELLP syndrome, in hypertensive disease in pregnancy. G.S. Arulkumaran S, Fernandez E, Editor. 2014, Jaypee Brothers Medical Publishers Ltd: India. p. 88-95.

  73. Ananth CV. Chronic hypertension and risk of placental abruption: is the association modified by ischemic placental disease? Am J Obstet Gynecol. 2007;197(3):273 e1-7.

  74. Haelterman E, Bréart G, Paris-Llado J, Dramaix M, Tchobroutsky C. Effect of uncomplicated chronic hypertension on the risk of small-for-gestational age birth. Am J Epidemiol. 1997;145(8):689-95.

  75. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol. 2011;31(6):465-72.

  76. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992;80(3 Pt 1):429-32.

  77. Rosa FW, Bosco LA, Graham CF, Milstien JB, Dreis M, Creamer J. Neonatal anuria with maternal angiotensin converting enzyme inhibition. Obstet Gynecol. 1989;74(3 Pt 1):371-4.

  78. Kincaid-Smith P, Bullen M, Mills J. Prolonged use of methyldopa in severe hypertension in pregnancy. Br Med J. 1966;1(5482):274-6.

  79. Ananth CV, Savitz DA, Bowes WA Jr, Luther ER. Influence of hypertensive disorders and cigarette smoking on placental abruption and uterine bleeding during pregnancy. Br J Obstet Gynaecol. 1997;104(5):572-8.

  80. Romero-Arauz JF. [Progression of gestational hypertension to preeclampsia]. Ginecol Obstet Mex. 2014;82(4):229-35.

  81. Anumba DO, Lincoln K, Robson SC. Predictive value of clinical and laboratory indices at first assessment in women referred with suspected gestational hypertension. Hyper Pregnancy. 2010;29(2):163-79.

  82. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba’aqeel H, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194(4):921-31.

  83. Buchbinder A, Sibai BM, Caritis S, Macpherson C, Hauth J, Lindheimer MD, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186(1):66-71.

  84. Steer PJ, Little MP, Kold-Jensen T, Chapple J, Elliott P. Maternal blood pressure in pregnancy, birth weight, and perinatal mortality in first births: prospective study. BMJ. 2004;329(7478):1312.

  85. Al Khaja KAJ, Sequeira RP, Alkhaja AK, Damanhori AH. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32(3):454-63.

  86. Mutch LM, Moar VA, Ounsted MK, Redman CW. Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life. Early Hum Dev. 1977;1(1):59-67.

  87. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1(8273):647-9.

  88. El-Qarmalawi AM, Morsy AH, al-Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet. 1995;49(2):125-30.

  89. Huisjes HJ, Hadders-Algra M, Touwen BC. Is clonidine a behavioral teratogen in the human? Early Hum Dev. 1986;14(1):43-8.

  90. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72.

  91. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301(6752):587-9.

  92. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol. 1997;79(10):1436-8.

  93. Yakoob MY, Bateman BT, Ho E, Hernandez-Diaz S, Franklin JM, Goodman JE, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension. 2013;62(2):375-81.

  94. Sorensen HT, Czeizel AE, Rockenbauer M, Steffensen FH, Olsen J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta Obstet Gynecol Scand. 2001;80(5):397-401.

  95. Danielsson BR, Reiland S, Rundqvist E, Danielson M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology. 1989;40(4):351-8.

  96. Scott WJ Jr, Resnick E, Hummler H, Clozel JP, Bürgin H. Cardiovascular alterations in rat fetuses exposed to calcium channel blockers. Reprod Toxicol. 1997;11(2–3):207-14.

  97. Brown MA, Buddle ML, Farrell T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gy necol. 2002;187(4):1046-50.

  98. Impey L. Severe hypotension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. Br J Obstet Gynaecol. 1993;100(10):959-61.

  99. Papatsonis DN, Lok CA, Bos JM, Geijn HP, Dekker GA. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;97(2):122-40.

  100. Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol. 1994;101(3):262-3.

  101. Ales K. Magnesium plus nifedipine. Am J Obstet Gynecol. 1990;162(1):288.

  102. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium- related maternal side effects in women with preeclampsia. Am J Obstet Gynecol. 2005;193(1):153-63.

  103. Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jick SS. Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy. 2013;33(5):476-82.

  104. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. Major congenital malformations after first trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-51.

  105. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev. 2006;82(1):23-8.

  106. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol. 2005;73(2):123-30.

  107. Groves TD, Corenblum B. Spironolactone therapy during human pregnancy. Am J Obstet Gynecol. 1995;172(5):1655-6.

  108. Spinnato JA, Sibai BM, Anderson GD. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. South Med J. 1986;79(5):559-62.

  109. Paterson-Brown S, Robson SC, Redfern N, Walkinshaw SA, de Swiet M. Hydralazine boluses for the treatment of severe hypertension in preeclampsia. Br J Obstet Gynaecol. 1994;101(5):409-13.

  110. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and betablockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20(2):138-45.

  111. Olsen KS, Beier-Holgersen R. Hemodynamic collapse following labetalol administration in preeclampsia. Acta Obstet Gynecol Scand. 1992;71(2):151-2.

  112. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955-60.

  113. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC; or the HYLA treatment study. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):157-62.

  114. Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2006;3:CD001449.

  115. Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, et al; Community Level Interventions for Pre-eclampsia (CLIP) Working Group. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8. discussion 1220.

  116. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354(17):1796-806.

  117. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH; Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 2006;367(9517):1145-54.

  118. Conde-Agudelo A1, Romero R, Kusanovic JP, Hassan SS. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology, 2011. 204(6).

  119. Basaran A, Basaran M, Topatan B. Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis. Obstet Gynecol Surv. 2010;65(10): 653-67.

  120. Romero R, Garite TJ. Unexpected results of an important trial of vitamins C and E administration to prevent preeclampsia. Am J Obstet Gynecol. 2006;194(5):1213-4.

  121. Banerjee S, Chambers AE, Campbell S. Is vitamin E a safe prophylaxis for preeclampsia? Am J Obstet Gynecol. 2006;194(5): 1228-33.

  122. Ramsay B, De Belder A, Campbell S, Moncada S, Martin JF. A nitric oxide donor improves uterine artery diastolic blood flow in normal early pregnancy and in women at high risk of preeclampsia. Eur J Clin Invest. 1994;24(1):76-8.

  123. Manzur-Verástegui S, Mandeville PB, Gordillo-Moscoso A, Hernández-Sierra JF, Rodríguez-Martínez M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe preeclampsia: a randomized, triple- blind, controlled trial. Clin Exp Pharmacol Physiol. 2008;35(5-6):580-5.

  124. Cetin A, Yurtcu N, Guvenal T, Imir AG, Duran B, Cetin M. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hyper Pregnancy. 2004;23(1):37-46.

  125. Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of preeclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol. 1998;12(5): 334-8.

  126. Schleussner E, Lehmann T, Kähler C, Schneider U, Schlembach D, Groten T. Impact of the nitric oxidedonor pentaerythrityl-tetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, doubleblinded trial. J Perinat Med. 2014;42(4):507-14.

  127. de Belder A, Lees C, Martin J, Moncada S, Campbell S. Treatment of HELLP syndrome with nitric oxide donor. Lancet. 1995;345(8942):124-5.

  128. Lees C, Langford E, Brown AS, de Belder A, Pickles A, Martin JF, et al. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol. 1996;88(1):14-9.

  129. Everett TR, Wilkinson IB, Mahendru AA, McEniery CM, Garner SF, Goodall AH, et al. S-Nitrosoglutathione improves haemodynamics in early-onset preeclampsia. Br J Clin Pharmacol. 2014;78(3): 660-9.

  130. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of preeclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009;338:b2255.

  131. Basso O, Christensen K, Olsen J. Higher risk of preeclampsia after change of partner. An effect of longer interpregnancy intervals? Epidemiology. 2001;12(6):624-9.

  132. Hargood JL, BrownMA. Pregnancy-induced hypertension: recurrence rate in second pregnancies. Med J Aust. 1991;154(6):376-7.

  133. Trogstad L, Skrondal A, Stoltenberg C, Magnus P, Nesheim BI, Eskild A. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A. 2004;126A(1):41-5.

  134. Facchinetti F, Neri I, Genazzani AR. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Investig. 1999;6(4):202-7.

  135. Cindrova-Davies T. The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia. Front Pharmacol. 2014;5:119.

  136. Fox KA. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011;205(4):366 e1-5.

  137. Kumasawa K1, Ikawa M, Kidoya H, Hasuwa H, Saito- Fujita T, Morioka Y, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108(4):1451-5.

  138. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One. 2010;5(10):e13663.

  139. Redecha P, van Rooijen N, Torry D, Girardi G. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood. 2009;113(17): 4101-9.

  140. National Institute for Health & Clinical Excellence (NICE). (CG37) Routine post-natal care of women and their babies. July 2006.

  141. Cantwell R. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The eighth report of the confidential enquiries into maternal deaths in the United Kingdom. BJOG. 2011;118 Suppl 1:1-203.

  142. Podymow T, August P, Umans JG. Antihypertensive therapy in pregnancy. Semin Nephrol. 2004;24(6):616-25.

  143. Redman CWG, Kelly JG, Cooper WD. The excretion of enalapril and enalaprilat in human breast-milk. Eur J Clin Pharmacol. 1990;38(1):99.

  144. Lunell NO, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol. 1985;28(5):597-9.

  145. Bramham K, Nelson-Piercy C, Brown MJ, Chappell LC. Postpartum management of hypertension. BMJ. 2013;346:f894.

  146. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev. 2007;2:CD004659.

  147. Van Rijn BB, Nijdam ME, Bruinse HW, Roest M, Uiterwaal CS, Grobbee DE, et al. Cardiovascular disease risk factors in women with a history of early-onset preeclampsia. Obstet Gynecol. 2013;121(5):1040-8.

  148. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.

  149. Melchiorre K, Sutherland GR, Liberati M, Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011;58(4):709-15.

  150. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/ eclampsia: a systematic review and meta-analyses. Am Heart J. 2008;156(5):918-30.

  151. Hannaford P, Ferry S, Hirsch S. Cardiovascular sequelae of toxaemia of pregnancy. Heart. 1997;77(2):154-8.

  152. Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM. A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens. 2014;32(4):849-56.

  153. Meah VL, Cockcroft JR, Stöhr EJ. Maternal cardiac twist pre-pregnancy: potential as a novel marker of preeclampsia. Fetal and Maternal Medicine Review. 2013:1-7. DOI: 10.1017/S0965539513000156

  154. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women–2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-62.

  155. Senter C, Appelle N, Behera SK. Prescribing exercise for women. Curr Rev Musculoskelet Med. 2013;6(2):164-72.

  156. American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 267: Exercise during pregnancy and the post-partum period. Obstet Gynecol. 2002;99:171-3.

  157. Magnus P, Trogstad, Owe KM, Olsen SF, Nystad W. Recreational physical activity and the risk of preeclampsia: a prospective cohort of Norwegian women. Am J Epidemiol. 2008;168(8):952-7.

  158. Marcoux S, Brisson J, Fabia J. The effect of leisure time physical activity on the risk of preeclampsia and gestational hypertension. J Epidemiol Community Health. 1989;43(2):147-52.

  159. Saftlas AF, Logsden-Sackett N, Wang W, Woolson R, Bracken MB. Work, leisure-time physical activity, and risk of preeclampsia and gestational hypertension. Am J Epidemiol. 2004;160(8):758-65.

  160. Vollebregt KC, Wolf H, Boer K, van der Wal MF, Vrijkotte TG, Bonsel GJ. Does physical activity in leisure time early in pregnancy reduce the incidence of preeclampsia or gestational hypertension? Acta Obstet Gynecol Scand. 2010;89(2):261-7.




2020     |     www.medigraphic.com